Imatinib pharmacokinetics and its correlation with response in chronic-phase chronic myelogenous leukemia

Imatinib pharmacokinetics and its correlation with response in chronic-phase chronic myelogenous leukemia - Imatinib pahrmacokinetics and response in CML

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000001125

Enrollment

Registered

2008-05-01

Start date

2008-05-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic myelogenous leukemia in chronic-phase

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Chronic myelogenous leukemia in 1st chronic-phase Pts on imatinib more than 1 year Pts on a regular maintenance dose at least 8 months during initial 1st year of imatinib therapy

Exclusion criteria

Exclusion criteria: Previous history of anti-leukemic therapy other than imatinib (except hydroxycarbamide at initial phase or steroids for non-anti-leukemia purposes) Pts taking drugs with known pahrmacokinetic interaction with imatinib Cr equal to or greater than 1.6mg/dl, AST/ALT equal to or greater than 2 times of NUL Positive serologic tests for syphilis, HBV or HCV

Design outcomes

Primary

Measure	Time frame
molecular response	—

Secondary

Measure	Time frame
cytogenetic response	—

Countries

Japan

Contacts

Public ContactTomoki Ueda

Keio University School of Medicine Novartis Pharma Program for Clinical Therapeutics of Hematologic Malignancy

Outcome results